Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.
As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up ...
The global proteinase K market is projected to grow from US$ 27.5 million in 2023 to US$ 43.9 million by 2033, at a CAGR of 4 ...
Increases speed to market for drug developers working on nucleic acid therapeutics.
Human Metapneumovirus (HMPV) primarily spreads through respiratory secretions from coughing or sneezing, close personal ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/97.TRc4SPmX.js ...
Evonik has partnered with ST Pharm to enhance its RNA and nucleic acid therapeutic services, combining ST Pharm's expertise in customized nucleic ...
Professor Kevin J. Zwezdaryk and Chandler H. Monk discuss CRISPR and diagnostics, focusing on the development of a portable ...
NV ("etherna"), a technology platform leader pioneering mRNA and lipid-based nanoparticle (LNP) technologies, announces a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback